STRO:NASDAQSutro Biopharma, Inc. Analysis

Sutro Biopharma is trading at $26.48, well below its 20‑day SMA of 29.26 and 50‑day SMA of 31.41, while the 200‑day SMA sits at 17.54, indicating a short‑term downtrend but long‑term neutrality. The RSI of 41.7 and a bearish MACD (line below signal, negative histogram) reinforce the technical weakness, and the stock faces a substantial 30‑day volatility of over 100% and a beta above 1, suggesting amplified market swings. Fundamentally, the company posted $99.6 M in revenue with a 16.5% decline year‑over‑year, and all margin metrics are deeply negative (gross margin –65.6%, operating margin –203.9%), while cash burn remains high (operating cash flow –$151 M). Despite a solid cash balance of $202 M and minimal debt, the negative free cash flow of $106 M raises runway concerns.
Recent material news includes a Wedbush upgrade to “Outperform” and an average analyst price target of $33.97, which is still above the current price but below the historical high of $43.85. The company is on track to release Phase 1 safety and early activity data for its lead ADC candidate STRO‑004, a potential best‑in‑class therapy for tissue‑factor‑expressing tumors, providing a catalyst that could shift sentiment. While the earnings outlook remains weak (trailing EPS –$16.35, forward EPS –$6.89), the pipeline momentum and analyst optimism support a more positive medium‑ to long‑term view.